Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)
NCT02244333
·
clinicaltrials.gov ↗
COMPLETED
Status
4575
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostatic Hyperplasia
Interventions
DRUG:
ALNA®
Sponsor
Boehringer Ingelheim